Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLC

Puneeth Iyengar, MD
Published Online: Monday, Oct 17, 2016



Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer (NSCLC).

The standard treatment for patients with stage III NSCLC includes both chemotherapy and radiation. However, a subset of patients cannot receive chemotherapy plus radiation because of medical comorbidities, explains Iyengar.

Thus, hypofractionated radiation accommodates that subset of patients by both increasing the potency of radiation as well as reducing the duration of treatment.


Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer (NSCLC).

The standard treatment for patients with stage III NSCLC includes both chemotherapy and radiation. However, a subset of patients cannot receive chemotherapy plus radiation because of medical comorbidities, explains Iyengar.

Thus, hypofractionated radiation accommodates that subset of patients by both increasing the potency of radiation as well as reducing the duration of treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Clinical Application of Biomarker Testing in NSCLCAug 02, 20172.0
Community Practice Connections™: Oncogenic Tumor Board in NSCLC: Targeting Driver Mutations to Maximize Therapeutic OutcomesAug 31, 20171.5
Publication Bottom Border
Border Publication
$emailPop$